LAX.SH
SUN PHARMACEUTICAL IND L·PHARMACEUTICALS 72.38·Pharmaceuticals & Biotechnology Companies
Price
1,942.6
+1.1%52W Range
Market Cap
₹4,66,094.81 Cr
Traded: ₹547.74 Cr (0.12%) 0.0x
Free Float: ₹34,770.67 Cr (1.58% of FF traded)
Volume · 60D trend
28.22 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | +7.0% | +12.0% | +10.0% | -- | +11.0% | Stable |
| Profit | +10.0% | +17.0% | +13.0% | -- | +9.0% | Decelerating |
| Return | +9.0% | +22.0% | +26.0% | +7.0% | -- | Stable |
| ROE | +14.0% | +16.0% | +16.0% | -- | -- | Stable |
Quarterly Results
Mar 2026
22 MayDec 2025
31 JanSep 2025
Jun 2025
Mar 2025
Dec 2024
Sep 2024
Jun 2024
Mar 2024
Dec 2023
Sep 2023
Jun 2023
Mar 2023
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 14,612 | 15,521 | 14,478 | 13,851 | 12,959 | 13,675 | 13,291 | 12,653 | 11,983 | 12,381 | 12,192 | 11,941 | 10,931 | 11,241 |
| Expenses | 10,658 | 10,572 | 9,951 | 9,550 | 9,243 | 9,666 | 9,352 | 9,045 | 8,948 | 8,904 | 9,013 | 8,609 | 8,129 | 8,237 |
| Operating Profit | 3,954 | 4,948 | 4,527 | 4,302 | 3,716 | 4,009 | 3,939 | 3,608 | 3,035 | 3,477 | 3,179 | 3,332 | 2,802 | 3,004 |
| OPM % | 27.0% | 32.0% | 31.0% | 31.0% | 29.0% | 29.0% | 30.0% | 29.0% | 25.0% | 28.0% | 26.0% | 28.0% | 26.0% | 27.0% |
| Other Income | 458 | 89 | 470 | -354 | 251 | 149 | 354 | 533 | 504 | 180 | 294 | -118 | 202 | 174 |
| Interest | 86 | 78 | 100 | 75 | 49 | 52 | 69 | 62 | 74 | 35 | 49 | 81 | 93 | 46 |
| Depreciation | 775 | 732 | 730 | 701 | 664 | 631 | 626 | 655 | 650 | 622 | 633 | 651 | 672 | 660 |
| Profit Before Tax | 3,551 | 4,227 | 4,168 | 3,173 | 3,254 | 3,476 | 3,598 | 3,424 | 2,816 | 3,000 | 2,791 | 2,481 | 2,240 | 2,471 |
| Tax % | 23.0% | 20.0% | 25.0% | 27.0% | 34.0% | 16.0% | 16.0% | 16.0% | 5.0% | 14.0% | 14.0% | 19.0% | 10.0% | 11.0% |
| Net Profit | 2,710 | 3,381 | 3,125 | 2,293 | 2,154 | 2,913 | 3,037 | 2,861 | 2,659 | 2,561 | 2,385 | 2,006 | 1,983 | 2,181 |
| Exceptional Items | 0 | -489 | 0 | -818 | -362 | -316 | 0 | 0 | -102 | -70 | 0 | -323 | -171 | 0 |
| EPS (Rs) | 11.3 | 14.0 | 13.0 | 9.5 | 9.0 | 12.1 | 12.7 | 11.8 | 11.1 | 10.5 | 9.9 | 8.4 | 8.3 | 9.0 |
| Sales Growth (YoY) | 12.8% | 13.5% | 8.9% | 9.5% | 8.1% | 10.4% | 9.0% | 6.0% | 9.6% | 10.1% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -5.9% | 7.2% | 4.5% | 6.9% | -5.2% | 2.9% | 5.0% | 5.6% | -3.2% | 1.6% | 2.1% | 9.2% | -2.8% | -- |
| OP Growth (YoY) | 6.4% | 23.4% | 14.9% | 19.2% | 22.4% | 15.3% | 23.9% | 8.3% | 8.3% | 15.7% | -- | -- | -- | -- |
| OP Growth (QoQ) | -20.1% | 9.3% | 5.2% | 15.8% | -7.3% | 1.8% | 9.2% | 18.9% | -12.7% | 9.4% | -4.6% | 18.9% | -6.7% | -- |
| Profit Growth (YoY) | 14.0% | 19.0% | 3.0% | 1.0% | -13.0% | 23.0% | 28.0% | 24.0% | 29.0% | 19.0% | 5.0% | 11.0% | 41.0% | 5.0% |
| EPS Growth (YoY) | 26.2% | 16.0% | 2.6% | -19.6% | -19.0% | 15.0% | 28.0% | 40.2% | 33.7% | 16.5% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -19.4% | 8.0% | 36.8% | 6.0% | -25.9% | -4.5% | 7.2% | 6.9% | 5.1% | 6.3% | 17.4% | 1.9% | -8.4% | -- |
| OP Margin | 27.1% | 31.9% | 31.3% | 31.1% | 28.7% | 29.3% | 29.6% | 28.5% | 25.3% | 28.1% | 26.1% | 27.9% | 25.6% | 26.7% |
| Net Margin | 18.6% | 21.8% | 21.6% | 16.6% | 16.6% | 21.3% | 22.9% | 22.6% | 22.2% | 20.7% | 19.6% | 16.8% | 18.1% | 19.4% |
| Material Cost % | 19.2% | 19.0% | 20.6% | 20.3% | 20.4% | 20.0% | 20.3% | 21.1% | 19.9% | 22.1% | 22.9% | 23.1% | 20.6% | 24.9% |
| Employee Cost % | 20.3% | 18.6% | 19.1% | 20.2% | 19.2% | 18.7% | 18.6% | 19.4% | 19.2% | 19.1% | 19.4% | 20.1% | 19.9% | 18.1% |
| P/S | 7.97 | 7.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 40.60 | 41.57 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 5.58 | 5.83 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Sun Pharma to announce first quarter results on 31 July 2026 Earnings call scheduled on Friday, 06.30 pm IST, 31 July 2026
Sun Pharmaceutical Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve Unaudited Standalone ....
Newspaper Publication
Investor Presentation -June 2026
Submission of Confirmation Certificate for the quarter ended 30 June 2026.
Notice of 34th Annual General Meeting along with the Annual Report for FY 2025-26
Annual Report 2025-26 and the Notice of 34th Annual General Meeting
Newspaper Advertisement
Closure of trading window
Acquisition of Innovcare Lifesciences Private Limited
Information about transfer of equity shares and unclaimed dividends to the Investor Education and Protection Fund (IEPF) Account
As attached
Intimation of Record Date
Intimation of Record Date for Final Dividend
Intimation of 34th AGM and Record Date for Final Dividend
Transcript for 22 May 2026 Analyst Meet
Intimation of Schedule of Analyst/Institutional Investor Meeting
Filing of Application for reclassification with stock exchanges
Press Release
Intimation of Schedule of Analyst/Institutional Investor Meeting
Newspaper publication for financial results for the year ended 31 March 2026
Q4FY26 Investor Call Audio Recording
Additional Outcome of the Board Meeting held today i.e., 22 May 2026
Recommendation of Final Dividend
Financial Results
Intimation of Newspaper publication for special window for transfer of physical shares
Intimation for receipt of request for reclassification of shareholders category
Earnings call for the financial results of the fourth quarter on 22 May 2026
Change in Board of Directors and Composition of Committees
Sun Pharmaceutical Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2026 ,inter alia, to consider and approve Audited Standalone ....
Completion and result of postal ballot dated 07 April 2026
Credit Rating
Transcript: Sun Pharma - Organon Acquisition Investor Call
Investor call audio recording related to the acquisition of Organon & Co.
Investor Presentation
Press Release
Sun Pharma signs Definitive Agreement to Acquire Organon
Incorporation of a Subsidiary Company
Outcome of Postal Ballot dated 17 March 2026
The Exchange has sought clarification from Sun Pharmaceutical Industries Ltd on April 10, 2026, with reference to news appeared in https://www.moneycontrol.com dated April 10, 2026 quoting ....
Intimation of newspaper advertisements about Postal Ballot/ E-Voting
Intimation of Notice of Postal Ballot for appointment of Ms. Satyavati Berera as an Independent Director
Submission of Confirmation Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31 March 2026
Appointment of Independent Director
Updates on Fibromun and Nidlegy
Press Release
Intimation for Trading window closure
Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India
Newspaper publication for Notice of Postal Ballot
Notice of Postal Ballot/E-voting
Annual Reports
15Credit Ratings
6Concalls
34Feb 2026
28 Feb 2026Dec 2025
31 Dec 2025Nov 2025
30 Nov 2025Sep 2025
30 Sept 2025Jul 2025
31 Jul 2025May 2025
31 May 2025Mar 2025
31 Mar 2025Jan 2025
31 Jan 2025Nov 2024
30 Nov 2024Oct 2024
31 Oct 2024Sep 2024
30 Sept 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Mar 2024
31 Mar 2024Feb 2024
29 Feb 2024Jan 2024
31 Jan 2024Nov 2023
30 Nov 2023Sep 2023
30 Sept 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Apr 2023
30 Apr 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Sep 2022
30 Sept 2022Aug 2022
31 Aug 2022Jun 2022
30 Jun 2022Mar 2022
31 Mar 2022Feb 2022
28 Feb 2022Nov 2021
30 Nov 2021Aug 2021
31 Aug 2021Aug 2021
31 Aug 2021Jun 2021
30 Jun 2021Jan 2021
31 Jan 2021Oct 2020
31 Oct 2020Held by ETFs
77 ETFs hold SUNPHARMA · sorted by weight
Held by Mutual Funds
30 schemes hold SUNPHARMA · sorted by weight